DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

 

Molecular Imaging Homepage

PET tracer may help assess promising Alzheimer's treatment Visualizing progress with 18F-AV45 PET imaging agent

New nanoparticle technology may replace MR for cancer detection Shows promise in preclinical study

US Nuclear Corp signs letter of intent to manufacture MIFTEC medical isotope generators Utilizes MIFTI's Staged Z-Pinch fusion technique

The five most important questions to ask about SPECT service Insights from Craig Snodgrass, national service manager at Universal Medical

Cerveau signs research contract with UV Medical Center in Amsterdam For the manufacture and supply of PET agent MK-6240

Expert makes the case for patient access to radiology reports Patients want a more active role in their care

MGH team develops a potential alternative to gadolinium-based contrast agents Made of the vital element manganese

Global PET/CT scanner market projected to reach $2.1 billion by 2023 Growth spurred in part by increased Medicare coverage

Can theranostics be the key to completely curing colorectal cancer? Preclinical trials yield promising results

Cerveau Technologies to collaborate in development of PET imaging agents for Alzheimer’s disease

Courtesy of Dr. Kambiz Rahbar

New therapeutic agent shows promise for treating deadly type of prostate cancer

by Lauren Dubinsky , Senior Reporter
A new therapeutic agent for radioligand therapy called lutetium-177-labeled PSMA-617 is showing promise in a German multi-center study for treating patients with metastatic castration-resistant prostate cancer. The research was recently published in The Journal of Nuclear Medicine.

Lu-177-PSMA-617 shows efficacy in patients independent of prior therapies,” Dr. Kambiz Rahbar of the University Hospital Muenster, told HCB News. “It has a favorable toxicity profile, especially compared to cytotoxic chemotherapy.”

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



Prostate-specific membrane antigen is overexpressed in prostate cancer, especially with castration-resistant disease. mCRPC is usually responsible for prostate cancer deaths and the median survival for men with the disease is less than two years.

As part of the study, 145 patients with mCRPC were treated with Lu-177-PSMA-617 at 12 therapy centers across Germany from February 2014 to July 2015. Each patient received one to four therapy cycles and a total of 248 therapy cycles were performed.

45 percent of patients had a positive
response following all therapy cycles
If the prostate-specific antigen amount decreased by 50 percent or more at least two weeks after the start of the therapy, the researchers considered it effective. They found that 45 percent of patients had a positive response after all of the therapy cycles and 40 percent responded after one cycle.

The patients experienced a few manageable side effects including hematoxicity, anemia, thrombocytopenia, leukopenia and dry mouth.

The researchers concluded that Lu-177-PSMA-617 radioligand therapy is safe and more effective than other third-line systemic therapies for mCRPC patients. However, more studies are needed to further validate its effectiveness in order for it to receive FDA approval.

“We think Lu-177-PSMA-617 will provide an additional therapeutic option for mCRPC and maybe as an additive therapy to established therapies at earlier stages to improve outcome,” said Rahbar.

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED